Cancer-Associated ThrOmboSIs - Patient-Reported OutcoMes With RivarOxaban (COSIMO) - Baseline characteristics and clinical outcomes.
Anthony MaraveyasJan Beyer-WestendorfAgnes Y LeeLorenzo G MantovaniYoriko De SanctisKhaled AbdelgawwadSamuel FatobaMiriam BachAlexander T CohenPublished in: Research and practice in thrombosis and haemostasis (2021)
In patients with CAT who changed to rivaroxaban treatment after ≥4 weeks of standard therapy, the observed incidence proportions of recurrent VTE and bleeding events were in keeping with the recognized effectiveness and safety profile of rivaroxaban for the treatment of CAT.